The Drugs Controller General of India (DCGI) has approved drug manufacturer Glenmark Pharmaceuticals to produce antiviral drug Favipiravir. The drug was launched in the Indian markets under the brand name FabiFlu. Priced at INR 103, FabiFlu can now be prescribed for Covid patients at mild to moderate conditions. The drug would be made available for the Indian market, as a 200 mg tablet with a strip of 34 tablets costing INR 3,500.
While commenting on the release of the drug, Glenmark officials maintained that the drug would be made available at both hospitals as well as retail units. The recommended dose of Favipiravir is 1,800 mg twice on day one, while the rest of the 14 days, patients need to undertake 800 mg twice a day.
